The cerebrospinal fluid Aβ1-42/Aβ1-40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer’s disease in a clinical setting

Manuscript Number: 

17-0327R1

Author(s): 
Adrien Albert, Maria Bjerke, Sarah Ceyssens, Peter Paul De Deyn, Ellen De Roeck, Sebastiaan Engelborghs, Johan Goeman, Peter Mariën, Ellis Niemantsverdriet, Julie Ottoy, Kristel Sleegers, Femke Soetewey, Charisse Somers, Steven Staelens, Sigrid Stroobants, Hanne Struyfs, Christine Van Broeckhoven, Sara Van Mossevelde, Tobi Van den Bossche, Jeroen Verhaeghe, Jan Versijpt, Leonie wyffels

Disclosures

Adrien Albert

  • Nothing to Disclose

Maria Bjerke

  • Nothing to Disclose

Sarah Ceyssens

  • Nothing to Disclose

Peter Paul De Deyn

  • Nothing to Disclose

Ellen De Roeck

  • Nothing to Disclose

Sebastiaan Engelborghs

  • Grants
    • Agency: 
      Janssen Pharmaceutica and ADx Neurosciences
      Dates: 
      1 0CT 2015 - 30 SEP 2021

Johan Goeman

  • Nothing to Disclose

Peter Mariën

  • Nothing to Disclose

Ellis Niemantsverdriet

  • Nothing to Disclose

Julie Ottoy

  • Nothing to Disclose

Kristel Sleegers

  • Nothing to Disclose

Femke Soetewey

  • Nothing to Disclose

Charisse Somers

  • Nothing to Disclose

Steven Staelens

  • Nothing to Disclose

Sigrid Stroobants

  • Nothing to Disclose

Hanne Struyfs

  • Nothing to Disclose

Christine Van Broeckhoven

  • Nothing to Disclose

Tobi Van den Bossche

  • Nothing to Disclose

Sara Van Mossevelde

  • Nothing to Disclose

Jeroen Verhaeghe

  • Nothing to Disclose

Jan Versijpt

  • Nothing to Disclose

Leonie wyffels

  • Nothing to Disclose